PortfoliosLab logo
Agile Therapeutics, Inc. (AGRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00847L1008

CUSIP

00847L100

IPO Date

May 23, 2014

Highlights

Market Cap

$10.43M

EPS (TTM)

-$1.70

Total Revenue (TTM)

$5.58M

Gross Profit (TTM)

$4.08M

EBITDA (TTM)

-$2.75M

Year Range

$0.31 - $1.49

Target Price

$5.00

Short %

7.50%

Short Ratio

0.28

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
AGRX vs. SPY
Popular comparisons:

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Agile Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%250.00%Oct 27Nov 03Nov 10Nov 17Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 26
-99.99%
217.77%
AGRX (Agile Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period


AGRX

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-6.75%

1M

-5.05%

6M

-5.60%

1Y

8.15%

5Y*

14.14%

10Y*

10.05%

*Annualized

Monthly Returns

The table below presents the monthly returns of AGRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20250.00%0.00%
2024-21.54%-48.04%-57.23%30.88%-18.88%291.69%3.96%-59.03%0.00%0.00%0.00%0.00%-69.12%
202318.94%-11.15%-6.63%-42.41%-41.24%-22.16%-1.69%-10.34%-7.69%-24.58%16.57%-7.58%-82.82%
2022-28.50%-12.32%-31.54%-72.67%-38.86%-16.79%-56.15%-21.22%-26.24%-6.03%-24.73%8.10%-98.84%
2021-1.74%1.77%-27.53%-11.06%-12.97%-17.39%-9.77%-3.33%-17.15%-17.45%-20.59%-22.52%-82.99%
202048.00%-27.70%-30.47%30.38%16.29%-1.42%-10.07%28.00%-5.00%-10.53%3.68%1.77%14.80%
201940.65%11.23%67.59%0.66%-17.76%16.80%-20.55%-5.17%7.73%1.27%75.00%19.05%334.10%
201821.93%10.67%-29.20%10.12%-80.21%-11.79%-40.69%-0.00%25.09%129.41%3.15%-33.60%-78.59%
2017-59.65%-3.48%44.37%12.01%-8.64%14.33%26.40%-27.43%29.65%6.50%5.47%-46.31%-52.81%
2016-37.50%-5.57%7.81%-6.76%38.17%-4.88%-8.02%3.43%-3.59%8.88%-9.61%-17.03%-41.60%
201541.69%24.60%-14.48%25.35%-18.59%-9.20%6.29%-3.29%-23.67%17.80%12.34%9.42%58.96%
20145.60%49.06%-28.33%35.04%-13.51%-2.74%-16.20%3.19%10.83%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AGRX is 48, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AGRX is 4848
Overall Rank
The Sharpe Ratio Rank of AGRX is 3838
Sharpe Ratio Rank
The Sortino Ratio Rank of AGRX is 7777
Sortino Ratio Rank
The Omega Ratio Rank of AGRX is 9292
Omega Ratio Rank
The Calmar Ratio Rank of AGRX is 1212
Calmar Ratio Rank
The Martin Ratio Rank of AGRX is 2323
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Agile Therapeutics, Inc. (AGRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There is not enough data available to calculate the Sharpe ratio for Agile Therapeutics, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio0.001.002.003.00Oct 27Nov 03Nov 10Nov 17Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 26
-0.18
1.81
AGRX (Agile Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Agile Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Oct 27Nov 03Nov 10Nov 17Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 26
-100.00%
-1.30%
AGRX (Agile Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Agile Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Agile Therapeutics, Inc. was 100.00%, occurring on Apr 1, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Apr 17, 20152254Apr 1, 2024
-45.35%Jun 25, 2014122Dec 16, 201449Feb 27, 2015171
-20.5%Mar 5, 201515Mar 25, 20158Apr 7, 201523
-9.22%Jun 4, 20142Jun 5, 20144Jun 11, 20146
-3.04%Jun 20, 20141Jun 20, 20141Jun 23, 20142

Volatility

Volatility Chart

The current Agile Therapeutics, Inc. volatility is 0.00%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%1.00%2.00%3.00%4.00%5.00%Oct 27Nov 03Nov 10Nov 17Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 260
4.26%
AGRX (Agile Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Agile Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items